Drugs / Quemliclustat
Quemliclustat
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07364214 | Feb → Apr 2026 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04104672 | Nov 2019 → Jul 2026 | malignant exocrine pancreas neoplasm | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/24 trials · 1 met primary | ||||||
| Phase 1/2 | NCT07667335 | Oct 2026 → Jul 2029 expected | infiltrating urothelial carcinoma, urinary bladder carcinoma, urothelial carcinoma | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05688215 | Mar 2023 → Dec 2026 expected | pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04660812 | May 2021 → Sep 2025 | colorectal cancer | Arcus Biosciences, Inc. | Completed | Met primary |
| Phase 1/2 | NCT04381832 | Jul 2020 → Aug 2024 | castration-resistant prostate carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06048484 | May 2024 → Apr 2027 expected | pancreatic ductal adenocarcinoma | Gulam Manji | Recruiting | No outcome recorded |
| Phase 2 | NCT06048133 | Mar 2024 → Jul 2026 overdue | cholangiocarcinoma | Nataliya Uboha | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05915442 | Jul 2023 → Dec 2026 expected | metastatic prostate carcinoma | Catherine Spina | Recruiting | No outcome recorded |
| Phase 2 | NCT05676931 | Feb 2023 → Dec 2027 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05329766 | Jun 2022 → Jan 2027 expected | digestive system cancer | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06608927 | Dec 2024 → Nov 2030 expected | pancreatic ductal adenocarcinoma | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04575311 Comparator | Oct 2020 → Sep 2021 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03677973 Comparator | Oct 2018 → Aug 2019 | — | Arcus Biosciences, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-07-10 | Arcus Biosciences, Inc. | Regulatory Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer arcusbio.com ↗
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer. |
| 2024-01-16 | Arcus Biosciences, Inc. | Results Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer arcusbio.com ↗
Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone |
| 2021-01-15 | Arcus Biosciences, Inc. | Results Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer arcusbio.com ↗
Across all four dose-escalation cohorts, no significant additive toxicity from AB680 plus NP/Gem plus zimberelimab has been observed beyond that expected from NP/Gem plus anti-PD-1 combined. |
| 2021-01-11 | Arcus Biosciences, Inc. | Results Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium arcusbio.com ↗
Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-10 | Arcus Biosciences, Inc. | Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer arcusbio.com ↗ |
| 2024-07-08 | Arcus Biosciences, Inc. | Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia arcusbio.com ↗ |
| 2024-01-16 | Arcus Biosciences, Inc. | Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer arcusbio.com ↗ |
| 2021-01-15 | Arcus Biosciences, Inc. | Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer arcusbio.com ↗ |
| 2021-01-11 | Arcus Biosciences, Inc. | Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium arcusbio.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quemliclustat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06048484 ↗ |
| Known as | AB680 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04575311 ↗ |
| Known as | COMPOUND 55 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4471306 ↗ |
| Action | Inhibit | “AB680 is a Cluster of Differentiation (CD)73 Inhibitor” NCT03677973 ↗ |
| Modality | Small molecule | — CHEMBL4471306 ↗ |
| Route | Intravenous | “AB680 will be administered as single and multiple intravenous doses” NCT03677973 ↗ |